Life Sciences Transactions
Life Sciences TransactionsWe regularly represent life sciences companies and investors in transactions critical to growth including venture financings, public offerings, mergers and acquisitions, and licensing agreements and collaborations.Learn More
Life Sciences Corporate Governance and Disclosure
Life Sciences Corporate Governance and DisclosureWith a team that includes former SEC senior staff members, our lawyers provide a unique combination of substantive knowledge, practical experience and skill.Learn More
Life Sciences Patent Litigation and Licensing Disputes
Life Sciences Patent Litigation and Licensing DisputesLife sciences companies turn to WilmerHale to resolve their most complex intellectual property disputes, including bet-the-company patent and licensing disputes, Hatch-Waxman litigation and litigation under the BPCIA.Learn More
Life Sciences Patents and Other Intellectual Property - Technical Experience
Life Sciences Patents and Other Intellectual Property - Technical ExperienceRepresenting leading companies in biotechnology, pharmaceuticals, diagnostics, medical devices and beyond in a wide variety of intellectual property matters.Learn More
Life Sciences Regulatory
Life Sciences RegulatoryHandling regulatory issues that arise for life sciences companies developing new drugs, biologics, devices, supplements and other products that require FDA approvals.Learn More
Life Sciences Securities Litigation and Enforcement
Life Sciences Securities Litigation and EnforcementLife sciences companies often find themselves the target of securities fraud litigation or investigations, and our experienced, interdisciplinary team has a strong record of achieving favorable results when these challenges arise.Learn More
Life Sciences Litigation
Life Sciences LitigationOur litigators have the insight to plan and execute a winning strategy from the outset of any case that our life sciences clients may face.Learn More
Life Sciences Real Estate Transactions
Life Sciences Real Estate TransactionsThe representation of landlords, tenants, developers and investors in life sciences transactions calls for sophisticated experience in light of the peculiar issues associated with startups, heavy upfront investment, integrity of laboratory space, environmental matters, security, decommissioning and related concerns.Learn More
Hot Topics in Life Sciences M&A: Milestones, Options and Reverse MergersEvent
LMG Life Sciences 2019 Recognizes WilmerHale as a Leading Law Firm for Life SciencesNews
Capital Markets TransactionsRepresented Arvinas, Constellation Pharmaceuticals, Stealth Biotherapeutics, Translate Bio and Trevi Therapeutics in recent IPOs, and the underwriters in the IPOs of Entasis Therapeutics, Rhythm Pharmaceuticals, TCR2 Therapeutics and Xeris Pharmaceuticals as well as clients in a broader selection of capital markets transactions including follow-on offerings and Rule 144A placements of convertible notes.
Licensing and Strategic AlliancesRepresented Apellis Pharmaceuticals in a development funding agreement with SFI Pharmaceuticals; Decibel Therapeutics in a strategic collaboration with Regeneron; MacroGenics in collaboration and licensing agreements with Incyte Corporation and Roche; Spark Therapeutics in a licensing and supply agreement with Novartis Pharmaceuticals; and Vividion Therapeutics in a strategic research collaboration with Celgene.
IP Counseling and Post-Grant ProceedingsSuccessfully representing a Danish pharmaceutical firm in a patent prosecution matter involving methods of treating Alzheimer’s Disease; successfully invalidating a patent through IPR proceeding on behalf of a global medical device company; facilitating settlements and wins at the PTAB through the IPR process, challenging six patents on behalf of a British multinational medical device company; and securing a significant victory for a global biopharmaceutical company when the PTAB rejected an IPR filed by the adverse party challenging our client’s patent related to their anticoagulant drug product.
Patent Litigation and Licensing DisputesAchieved a significant victory on behalf of multiple medical device and diagnostics companies in an infringement suit filed by a biotechnology company when the District of Delaware granted summary judgment invalidating the key patent asserted against our clients; successfully represented a biopharmaceutical company at the Federal Circuit involving a patent covering its parent company’s blockbuster oncology drug; prevailed on behalf of a pharmaceutical company at the Federal Circuit pertaining to its colonoscopy prep kit product; obtained a trial victory and Federal Circuit affirmance in favor of a British pharmaceutical company, involving a patent covering its prostate cancer treatment; provided ongoing representation of two global biopharmaceutical companies against 25 different generic companies concerning the Orange Book–listed patents for their anticoagulant drug product; represented a pharmaceutical research and development company in some of the first litigations arising under the Biologics Price Competition and Innovation Act in relation to biosimilars of the company’s immunosuppressive drug; and represented clients in litigation and arbitration involving licensing disputes.
Venture Capital FinancingsRepresented Carisma Therapeutics in its $53 million Series A financing, Decibel Therapeutics in its $55 million Series C financing, Generation Bio in its $100 million Series B financing, Pandion Therapeutics in its $58 million Series A financing, Ribometrix in its $30 million Series A financing, Ribon Therapeutics in its $65 million Series B financing, Schrödinger in its $85 million late stage financing, and numerous others. Also represent leading life sciences venture funds and other strategic investors, such as Atlas Venture, Flagship Pioneering, MPM Capital, Sofinnova Ventures and many others, in financings.
M&ARepresented Arsanis in its sale to X4 Pharmaceuticals for $165 million, Exonics Therapeutics in its sale to Vertex Pharmaceuticals for $245 million (not including contingent payments), Potenza Therapeutics in its sale to Astellas Pharma for $405 million (including contingent payments), PTC Therapeutics in its acquisition of Agilis Biotherapeutics for $200 million and Thermo Fisher Scientific in the sale of its anatomical pathology business to PHC Holdings for $1.14 billion.
Securities Fraud Litigation and SEC InvestigationsDefend clients in federal securities fraud class action suits, derivative suits, and US Securities and Exchange Commission investigations related to disclosures surrounding the progress of clinical trials, the FDA approval process, and product safety and efficacy. Successful representations include recent wins on behalf of Tetraphase Pharmaceuticals, ConforMIS, InVivo Therapeutics, AVEO Pharmaceuticals, Medtronic, and many others.
Real Estate TransactionsRepresented a New York Stock Exchange publicly traded real estate investment trust in multiple transactions, including leasing matters, joint ventures, acquisitions, financings and development projects for office, lab and retail complexes in key life sciences cluster locations; represented a real estate developer that specializes in healthcare facilities in the acquisition, leasing and development of the first-ever proton therapy center in New York City; and counseled a global pharmaceutical company in the development of its more than a million-and-a-half square-foot campus in Cambridge, Massachusetts, from the time it chose to shift its major research headquarters from Europe to Cambridge through the present.
Trade Industry RepresentationRepresented Pharmaceutical Research and Manufacturers of America (PhRMA) as amicus before the Second and Third Circuit Courts of Appeals addressing two antitrust issues of significance to the industry: Hatch-Waxman reverse payment settlements, and so-called “product hopping” claims. On behalf of PhRMA, we submitted antitrust briefs addressing product hopping to the Second Circuit in the Namenda case, and to the Third Circuit in the Doryx case. We also submitted an amicus brief addressing reverse payments to the Third Circuit in Wellbutrin.
Recognized as a Top Law Firm for Life Sciences
Named WilmerHale Life Cycle Firm of the Year
LMG Life Sciences
Ranked WilmerHale Among the Top Law Firms for Life Sciences
The Legal 500 US
- Chambers USA: America’s Leading Lawyers for Business - Named WilmerHale a top law firm for life sciences from 2007–2019 with sources saying our attorneys are “great at teamwork” and “they're also hiring very good juniors,” “a longstanding team which works very well together,” in which “everyone speaks openly and adds to the solution,” “responsive, efficient and very technically sophisticated,” “best in class” and “highly professional with a broad range of experience.”
- LMG Life Sciences - Named WilmerHale the US Life Cycle Firm of the Year in 2017–2019 and among the shortlist from 2012–2019, and in 2019 named the firm General Patent Litigation Firm of the Year and Intellectual Property Firm of the Year. The firm was awarded a Hatch-Waxman Impact Case of the Year Award in 2018 and Finance and Transactional Impact Case of the Year Award in 2017. LMG has also ranked the firm in its 2012–2019 editions in patent prosecution, patent strategy and management, general patent litigation, Hatch-Waxman patent litigation, corporate, licensing and collaboration, M&A, venture capital and white collar/government investigations, and named 18 WilmerHale lawyers as “life sciences stars.”
- Managing IP - Recognized WilmerHale as one of the best in the United States for life sciences from 2013–2019. In 2013, 2016, 2017 and 2019-2020, WilmerHale was named the Patent Contentious Firm of the Year and in 2013, the Pharmaceutical IP Litigation Firm of the Year.
- The Legal 500 US - Ranked WilmerHale among the top law firms for life sciences from 2013–2019 with sources saying the “team excels in litigation, as well as transactional and IP matters,” and the firm “brings a great deal of experience to any situation” and “has access to additional expertise/resources to help solve any problem.”
- U.S. News - Best Lawyers® - Recognized the firm in its 2014–2020 Best Law Firms lists in the first tier nationally for biotechnology law, corporate law, intellectual property litigation, mergers & acquisitions law, patent law, securities/capital markets law, securities litigation and venture capital law. For 2019–2020, WilmerHale received first-tier metropolitan rankings in Boston, Colorado, New York, San Jose and Washington DC for several of these and other practice areas relevant to the life sciences industry.
- Chambers Global - Recognized WilmerHale as a leader in life sciences since 2013, and in 2020, acknowledged the firm for global work in the sector including cross-border IP disputes, patent litigation, investigations, regulatory matters and transactions with sources praising “the firm's capacity to navigate the complexities of the regulatory environment in the global life sciences industry” and WilmerHale’s “strong offering across both sides of the Atlantic.”
- FierceBiotech - Named Voyager Therapeutics' strategic collaboration—led by WilmerHale—with Neurocrine Biosciences as one of the top 15 biopharma licensing deals of 2019.
- In Vivo - Named Regeneron’s novel deal with Decibel Therapeutics, represented by WilmerHale, as the Top Alliance 2017 Deal of the Year.
- Lake Whillans - The Life Sciences Law Firm Index, published from 2016–2017, included WilmerHale among the top three life sciences law firms (2016, 2017), as the top firm for startup work (2017), among the top 10 deal firms (2017), the top two patent law firms (2016) and top 10 firms for thought leadership (2016).
- The BTI Consulting Group Inc. - Named WilmerHale among the top 10 law firms for having strong and lasting client relationships with the pharmaceutical industry in its BTI Power Rankings 2017 report.